FOXTROT™ PRO
Gains Market Approval in Indonesia

FOXTROT™ PRO PTCA Balloon Dilatation Catheter ("FOXTROT™ PRO"), a product in-house developed by Shanghai MicroPort Medical (Group) Co ("MicroPort"), recently received approval for market launch in Indonesia.

FOXTROT™ PRO is a rapid exchange balloon catheter for percutaneous transluminal coronary angioplasty ("PTCA"). Made of advanced balloon material, FOXTROT™ PRO has superior crossability and trackability. It features smooth tip with the unique “soft-tip.” The distal tip is seamlessly bonded by advanced laser welding technique. Its super-long hydrophilic coating largely enhances its pushability and crossability, and its best-in-class shaft profile offers full capability of kissing balloon through

As MicroPort’s second generation of PTCA balloon catheter after JIVE™ PTCA Balloon Catheter, FOXTROT™ PRO has gained market approval in Thailand, Argentina and Brazil. As it is permitted to launch in Indonesia, MicroPort* will further expand our overseas market and diversify our cardiovascular product line.
Tubridge™
Granted Green Channel Status for CFDA Approval

Tubridge™ Vascular Reconstruction Device ("Tubridge™"), an innovative product of MicroPort NeuroTech (Shanghai) Co ("MicroPort® NeuroTech"), was granted Green Channel status to fast track for China Food and Drug Administration ("CFDA") approval on February 3. This will significantly shorten the approval time, and therefore benefiting more Chinese patients earlier than expected.

Tubridge™ was studied in a prospective, randomized, controlled clinical trial with participation of 12 leading neurovascular intervention centers in China. The results of the trial demonstrated the safety and efficacy of this innovative device in the treatment of large or giant cerebral aneurysms, and were significantly better than the traditional stent-assisted coil embolization technique. The study protocol was published in BMC Neurology, a journal of the prevention, diagnosis and management of neurological disorders.

A cerebral aneurysm is a weak or thin spot on a blood vessel in the brain that balloons up and fills with blood. It is the main cause of subarachnoid hemorrhage. The bulging aneurysm can put pressure on a nerve or surrounding brain tissue. Aneurysms can later burst and bleed into the brain, causing serious complications or even death. Larger aneurysms are the most dangerous, with high aneurysmal rupture rate, high treatment cost, complex operating procedure and high recurrence rate.
MicroPort® EP Attends the 8th Atrial Fibrillation Key Technology International Forum

Shanghai MicroPort EP MedTech Co ("MicroPort® EP") recently attended the 8th Atrial Fibrillation Key Technology International Forum held from January 29 to January 30 in Beijing. Hosted by Chinese Heart Rhythm Society and Beijing Lisheng Cardiovascular Health Foundation, the forum provided a platform for domestic and international electrophysiologists to discuss the latest developments of technologies and methods used in ablation procedure.


As the first domestically made 3D EP navigation system with electromagnetic device tracking and full catheter curve display, Columbus® attracted wide attention from experts in attendance. Professor Yansheng Ding of Peking University First Hospital, Professor Changsheng Ma of Beijing Anzhen Hospital of Capital Medical University and Professor Heng Cai of Tianjin Medical University General Hospital visited MicroPort® EP booth to try the devices and spoke highly of the performances of Columbus® and FireMagic® Cool 3D.

Columbus® is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation and accurate geometric reconstruction of intra cardiac chambers; and FireMagic® Cool 3D helps physicians effectively maneuver the ablation catheter in the body during procedures by providing precise location of the catheter curve in the body and collecting cardiac ECG signals. The use of Columbus® combined with FireMagic® Cool 3D provides physicians with a comprehensive solution for the diagnosis and treatment of complex arrhythmias.

Columbus® was granted CE approval in 2013 and is the only domestically made 3D EP navigation system with the CE certificate. In 2015, it was granted Green Channel status to fast track for CFDA approval, which will significantly shorten the approval period to benefit more Chinese patients earlier than expected.
Reewarm™ PTX Granted Green Channel Status for CFDA Approval

Reewarm™ PTX Drug Coated Balloon Dilation Catheter ("Reewarm™ PTX"), independently developed by MicroPort Endovascular (Shanghai) Co ("MicroPort® Endovascular"), was recently granted Green Channel status to fast track for CFDA approval.

Reewarm™ PTX is a drug-coated OTW balloon dilation catheter, designed for the treatment of peripheral arterial diseases. The catheter is inserted into a vessel with the balloon assembly in an un-inflated form. The balloon is positioned at peripheral arterial lesion and inflated to open the narrowed vessel. The coated drug paclitaxel is transported to the lesion vessel wall once the inflated balloon touches the arterial wall. Then the balloon is deflated and taken out of the body. The paclitaxel remains on the vessel wall in a certain form over a certain period of time to inhibit the proliferation of smooth muscle cell, so as to prevent the vessel restenosis.

The innovative Green Channel for CFDA approval was an important approach introduced by the government administration to encourage the innovations of medical devices and promote the application of new technologies in the healthcare industry.
MicroPort® Orthopedics Donates Hip Prosthesis in a Charitable SuperPath™ Surgery

In partnership with the Fifth Affiliated Hospital of Southern Medical University, Shanghai MicroPort Orthopedics Co (“MicroPort® Orthopedics”) recently helped a disadvantaged patient to walk again after staying in bed for four months.

The patient, 67, broke his right neck of femur in September but failed to receive treatment promptly as he cannot afford the surgery. After learning the situation, the Fifth Affiliated Hospital of Southern Medical University reached out to an NGO to fund the surgery and MicroPort® Orthopedics donated a hip prosthesis needed in the treatment. With their help, the patient received a free Total Hip Arthroplasty surgery using the SuperPath™ Hip technique, and managed to walk on the next day after the surgery.

Chenglong Pan, who conducted the surgery, spoke highly of the SuperPath™ hip technique, which was introduced to China from 2014 by MicroPort® Orthopedics. He pointed out, a SuperPath™ hip replacement is designed to precisely reconstruct the hip without cutting critical tendons and stretching or traumatizing muscles that are important to hip function, and because of the elimination of damage to the important structures during reconstruction, patients typically have a short hospital stay, which offers them a more rapid return to function.

MicroPort® Orthopedics is committed to serving patients with joint diseases. We hope to benefit more patients through medical innovations and charitable giving.
MicroPort® Awarded
Five Star Credit Enterprise

MicroPort® recently awarded the honorable distinction of “Five Star Credit Enterprise” by a committee under Shanghai Municipal Government, which is the highest honor of Shanghai Credibility Construction Program.

MicroPort® started to take part in Shanghai Credibility Construction Program from 2010, and was granted one-star to four-star credit enterprise awards respectively between 2011 and 2014. This five-star award showed that MicroPort®’s effort in building up an integrity system in the company was fully recognized by the committee and the society. Integrity is one of MicroPort®’s eight key values. We are determined to demonstrate our integrity through quality products and service.

Under the direction of 20 departments of Shanghai Municipal Government, Shanghai Credibility Construction Program is designed to promote the construction of Shanghai credibility system and improve the intangible infrastructure of Shanghai’s economic and social development.
For more information, please contact:

**Hongbin Sun**
Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600
Email: ir@microport.com